In June 2024, the pharmaceutical industry faced a new practice by the Federal Antimonopoly Service (FAS), which began to consistently recognize the introduction of generic drugs onto the market as unfair competition.
The new review of the most notable patents disputes in Life Sciences in Russia and CIS.
Partner and Head of the Lidings’ Intellectual Property practice Boris Malakhov will take part in an annual conference entitled Intellectual Property - 2025 organized by Pravo.ru. The conference will take place on 21 November 2025 in Baltschug Kempinski.
Lidings is pleased to invite you and your colleagues to a seminar on launching new drugs in the Russian market.
Regulatory incentives and objective economic realities are driving pharmaceutical companies to seek opportunities for launching new drugs. Such projects are now being conceived and implemented not only by innovative companies but also by players who have traditionally specialized in generics and biosimilars.
During our seminar, we will share our experience and propose effective, cost-efficient legal solutions to help businesses safely and promptly execute new launches at any stage.
April 10th, 2025 annual conference Pharmaceuticals – 2025: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.
As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2024 and what awaits us in 2025.
The State Duma is considering the bill No. 818556-8 “On Amendments to Part Four of the Civil Code of the Russian Federation” (the “Bill”), the authors of which propose to amend the procedure for making decisions on the use of inventions, utility models and industrial designs (“Objects of patent rights”) established by Article 1360 of the Civil Code of the Russian Federation.
The new review of the most notable patents disputes in Life Sciences in Russian and the CIS.
Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.
On November 21- 22, 2024, Moscow will host the IX Conference “Legal Business of Russia 2024” with Lidings’ partner Boris Malakhov taking part as an invited expert.
The site uses cookie technology to ensure optimal performance, analyze usage and improve user experience. By continuing to use the site, you consent to the placement of cookies on your device on the terms set out in the Privacy Policy.
To ensure optimal performance, analyze usage and improve user experience, the website may use web analytics systems (including Yandex.Metrica), which may place cookies on your device.
By continuing to use the website, you agree to the use of these technologies and the placement of cookies. You can delete cookies from your device through your browser settings and you can block the placement of cookies, however, in doing so, some website features may not be available due to the engine's technological limitations.
You can find more information in the Privacy Policy.